As a practical matter, if the Dr. visits are delayed that is not a show stopper as long as the subjects still have their 2-73 to take.
The result will be delayed on follow up data taking visits. That is not all bad news. The effect is to have a long trial. There will be a longer interval in taking data on some data points. That is not in and of itself a big issue, especially of the delay is not a big one.
What will matter is the data taken at the end point of the trial whenever it is.
The key is making sure that the study participants still have their drug to take. That can be handled by the mails if they can't come into the study facilities as expected.
Market Data 
Markets 
AI
